Relypsa Inc RLYP 3.98% shareholders are enjoying yet another double-digit gain in Friday’s session on news that the FDA has rejected AstraZeneca plc (ADR) AZN 0.84%’s recently-acquired hyperkalemia drug ZS-9. Today isn’t the first time this year that Relypsa shareholders have been treated to double-digit one-day gains.

In fact, it’s happened five other times.

• 1. January 20: At one point, Relypsa was up as much as 16.3 percent following the release of an Oppenheimer note saying that the Relypsa sell-off to start the year was overdone.
• 2. January 26: Relypsa surged more than 15.1 percent following the release of positive Phase I results on key drug candidate Veltassa.
• 3. February 11: Relypsa was up as much as 10.6 percent after Spherix Global Insights said that Veltassa was “off to a strong start.”
• 4. April 7: The biggest move of the year was…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!